Prof Kausik Ray FMedSci
@ProfKausikRay
Followers
6K
Following
15K
Media
637
Statuses
6K
Immediate Past President EAS, Professor of Public Health, Imperial College London. Cardiologist focusing on preventing coronary artery disease
London, England
Joined February 2018
A paper in EJPC on predictors of CRP with an editorial by Paul Ridker. Simplest thing is to measure it. If cost is an issue then here are variables that help predict elevated levels. I showed this in 2005 in JACC. Essentially unchanged in UKBB and NHANES https://t.co/bVkgIdg0MD
academic.oup.com
AbstractAim. Novel therapies are under evaluation for upstream inhibition of inflammatory pathways in atherosclerotic cardiovascular disease (ASCVD). Eleva
0
5
7
What's the latest guidance on #LipidManagement for #cardiology professionals? Despite a plethora of available therapies, there is room for improvement! @ProfKausikRay, Assoc Prof Margrét Leósdóttir, & Prof Dr Klaus G. Parhofer discuss: https://t.co/gZgmYZ7kPA
#MedEd #CME
0
2
5
The EAS Advanced Courses on Rare Lipid Disorders continue their mission of providing state-of-the-art education for clinicians and researchers. On November 28, we welcome you to Berlin for the next course, hosted in collaboration with our German colleagues - D•A•CH-Gesellschaft
2
7
18
Here I am in 2020 in the flimsiest, most pitful PPE - like so many other NHS staff, some of whom died from the Covid they caught in their hospitals. Tory peer @MichelleMone - who today rightly (& wonderfully) lost her legal case - dares to claim she’s been ‘scapegoated’. What,
918
6K
22K
Mabs reduce Lp(a) and LDL-C, LDL-C reductions similar in all gps irrespective of Lp(a). modest Lp(a) lowering with mabs may contribute to early benefit when Lp(a) is high or a high Lp(a) associates with more vulunerable plaques who derive earlier benefit from Alirocumab post ACS
1
2
3
Among those with Lp(a) > 50mg/dl time to benefit Upper CI <1 for MACE and stays below 1 is ~ 1.24 yr vs 3 years for those with Lp(a) <50mg/dl Similarly Major limit event benefits observed only in those with elavted Lp(a) and again rapidly < 6 months
1
1
3
Our latest paper Lipoprotein(a) levels and time to cardiovascular benefit with Alirocumab in patients with recent acute coronary syndrome Published open access in JACC https://t.co/Ip7yqe8Gqn
1
6
19
The EU High-Level Event on cardiovascular health is happening right now at the European Parliament 🇪🇺. Patients, policymakers & experts are coming together to highlight why early screening for FH and Lp(a) must become a European priority. @ProfKausikRay @KatiOorni
0
7
23
Today is FH awareness day. Fittingly I had a patient who “was not good at remembering meds @25 I pointed out your grandfather was detected at 60, your father at 20, you at 5. Each generation bought the next the gift of time. Don’t waste it. Much to do
2
7
17
European Heart Journal Review: Early and Intensive LDL-C Reduction Cuts Events Post-ACS @ehj_ed | @ProfKausikRay
https://t.co/Pzp8xk5cTc
#AcuteCoronarySyndrome #Cardiology #Lipid #MedEd #CardiovascularEvents #Cholesterol #Thrombosis #EuropeanHeartJournal #Health #Hematology
0
3
9
In people with #diabetes who are unable or unwilling to tolerate guideline-recommended doses of #statins, bempedoic acid provides substantial #cardiovascular benefits. Read the full prespecified analysis of the CLEAR outcomes RCT here:
thelancet.com
Among patients with diabetes, bempedoic acid reduces LDL cholesterol and high-sensitivity C-reactive protein and risk of cardiovascular events. Patients without diabetes had no increase in new-onset...
1
14
34
Evidence is clear: the earlier and deeper the LDL-C drop post-acute coronary syndrome, the fewer cardiovascular events. Time to rethink cholesterol targets with combination therapy. Read more in #EHJ. https://t.co/vSpxHzFJlh
#ACS #Cholesterol #cardiotwitter @ESC_Journals
2
31
108